Literature DB >> 16513678

Transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer.

Laura P Stabile1, Jennifer S Lyker, Stephanie R Land, Sanja Dacic, Beth A Zamboni, Jill M Siegfried.   

Abstract

Several studies have suggested a possible role of the hepatocyte growth factor (HGF)/c-Met system in lung tumor development and progression. Extent of expression of both HGF and c-Met have been shown to be negative prognostic indicators of survival and recurrence in non-small-cell lung cancer, especially adenocarcinoma. To further define a role for HGF in lung cancer development and growth, we have generated transgenic mice that overexpress HGF in the airway epithelium. HGF transgenic and wild-type mice were exposed to the tobacco carcinogen, nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), or saline control and killed 10-38 weeks after exposure. Lungs were formalin inflated, paraffin embedded and sectioned. It was verified that the HGF transgene was expressed only in the lungs of transgenic mice. The transgenic mouse lung histology exhibited congestion in the alveolar spaces, excess production of blood vessels and a convoluted pattern of airways with wide bifurcations. The number of lung tumors from NNK-treated transgenic animals versus the number of lung tumors from NNK-treated wild-type animals was significantly higher (P = 0.0001, Poisson regression). The percentage of animals with tumors was 75% in the transgenic group compared with 48.8% in the wild-type group. The main effect was an increase in tumor multiplicity; average size of tumors was not different between the groups. Additionally, the tumors that arose in the transgenic mice contained increased HGF protein compared with tumors from the wild-type mice. These results indicate that lung carcinogenesis induced by a tobacco carcinogen is enhanced by expression of the HGF transgene. This model recapitulates the phenotype of aggressive lung adenocarcinoma that overexpresses HGF and will be useful in evaluating antitumor agents that target either the HGF/c-Met pathway or downstream effects such as angiogenesis or invasion.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16513678     DOI: 10.1093/carcin/bgl003

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  21 in total

Review 1.  Biology of MET: a double life between normal tissue repair and tumor progression.

Authors:  Iacopo Petrini
Journal:  Ann Transl Med       Date:  2015-04

2.  The MET axis as a therapeutic target.

Authors:  Martin Sattler; Ravi Salgia
Journal:  Update Cancer Ther       Date:  2009-04-01

3.  Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.

Authors:  Hai Xu; Laura P Stabile; Christopher T Gubish; William E Gooding; Jennifer R Grandis; Jill M Siegfried
Journal:  Clin Cancer Res       Date:  2011-05-27       Impact factor: 12.531

4.  The role of the c-Met pathway in lung cancer and the potential for targeted therapy.

Authors:  Martin Sattler; Mamatha M Reddy; Rifat Hasina; Tara Gangadhar; Ravi Salgia
Journal:  Ther Adv Med Oncol       Date:  2011-07       Impact factor: 8.168

5.  HGF/c-Met overexpressions, but not met mutation, correlates with progression of non-small cell lung cancer.

Authors:  Mukaddes Gumustekin; Aydanur Kargi; Gulay Bulut; Aysim Gozukizil; Cagnur Ulukus; Ilhan Oztop; Nese Atabey
Journal:  Pathol Oncol Res       Date:  2011-07-21       Impact factor: 3.201

Review 6.  c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy.

Authors:  Martin Sattler; Ravi Salgia
Journal:  Curr Oncol Rep       Date:  2007-03       Impact factor: 5.075

7.  Co-targeting c-Met and COX-2 leads to enhanced inhibition of lung tumorigenesis in a murine model with heightened airway HGF.

Authors:  Laura P Stabile; Mary E Rothstein; Christopher T Gubish; Diana E Cunningham; Nathan Lee; Jill M Siegfried
Journal:  J Thorac Oncol       Date:  2014-09       Impact factor: 15.609

8.  Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis.

Authors:  Laura P Stabile; Mary E Rothstein; Phouthone Keohavong; Jide Jin; Jinling Yin; Stephanie R Land; Sanja Dacic; The Minh Luong; K Jin Kim; Austin M Dulak; Jill M Siegfried
Journal:  Mol Cancer Ther       Date:  2008-07       Impact factor: 6.261

9.  Prevention of Tobacco Carcinogen-Induced Lung Tumor Development by a Novel STAT3 Decoy Inhibitor.

Authors:  Christian Njatcha; Mariya Farooqui; Abdulaziz A Almotlak; Jill M Siegfried
Journal:  Cancer Prev Res (Phila)       Date:  2020-07-12

10.  Prevention of tobacco carcinogen-induced lung cancer in female mice using antiestrogens.

Authors:  Laura P Stabile; Mary E Rothstein; Diana E Cunningham; Stephanie R Land; Sanja Dacic; Phouthone Keohavong; Jill M Siegfried
Journal:  Carcinogenesis       Date:  2012-08-02       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.